Heterocycle-based MMP inhibitors with P2' substituents.
Pikul, S., Dunham, K.M., Almstead, N.G., De, B., Natchus, M.G., Taiwo, Y.O., Williams, L.E., Hynd, B.A., Hsieh, L.C., Janusz, M.J., Gu, F., Mieling, G.E.(2001) Bioorg Med Chem Lett 11: 1009-1013
- PubMed: 11327577 
- DOI: https://doi.org/10.1016/s0960-894x(01)00137-8
- Primary Citation of Related Structures:  
1D8M, 1G05 - PubMed Abstract: 
Potent and selective inhibition of matrix metalloproteinases was demonstrated for a series of sulfonamide-based hydroxamic acids. The design of the heterocyclic sulfonamides incorporates a six- or seven-member central ring with a P2' substituent that can be modified. Binding interactions of this substituent at the S2' site are believed to contribute to high inhibitory potency against stromelysin, collagenase-3 and gelatinases A and B, and to provide selectivity against collagenase-1 and matrilysin. An X-ray structure of a stromelysin inhibitor complex was obtained to provide insights into the SAR and selectivity trends observed for the series.
Organizational Affiliation: 
Procter and Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA. spikul@avalonrx.com